Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.
You may also be interested in...
CBER To Train Foreign Regulators On Biologics Review
October seminar is planned in response to international requests; CDER will hold companion forum.
CBER To Train Foreign Regulators On Biologics Review
October seminar is planned in response to international requests; CDER will hold companion forum.
REMS Not Anticipated For Every NME – FDA Official
CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.